Daratumumab (Darzalex®) for use in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/10/17|
|Rapid review completed||27/11/17|
|Rapid Review Outcome||A full pharmacoeconomic evaluation is recommended.|
|Full pharmacoeconomic assessment commissioned by HSE||29/11/2017|
|Pre-submission consultation with Applicant||23/01/2018|
|Submission received from Applicant||21/09/2018|
|Preliminary review sent to Applicant||30/11/2018|
|NCPE assessment re-commenced||20/12/2018|
|Factual accuracy sent to Applicant||05/02/2019|
|NCPE assessment re-commenced||13/02/2019|
|NCPE assessment completed||15/03/2019|
|NCPE assessment outcome||
The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.